Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJian LiMZMincui ZhengSLSixi Liu

Discussion

Loading...

Member takes

Overview

Multicenter cohort study reveals FLAG-IDA's significant survival benefit in pediatric acute myeloid leukemia with core-binding factor.

Key Points

  • FLAG-IDA induction therapy yields better overall survival in pediatric acute myeloid leukemia patients, especially those with core-binding factor.
  • Five-year overall survival for FLAG-IDA was 79.6%, significantly higher than the 69.3% seen with DAE therapy.
  • This retrospective cohort study evaluated 875 pediatric patients receiving FLAG-IDA or DAE as induction therapy.
  • Study supports use of FLAG-IDA as frontline treatment, indicating potential for reduced chemotherapy duration.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8a3https://doi.org/10.1182/blood-2025-5152
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial2025
  2. 2FLAG-mitoxantrone combined with low-dose venetoclax (7 Days): A highly efficient regimen and excellent bridge for allogeneic hematopoietic transplant for newly diagnosed and relapsed/refractory AML.2025
  3. 3Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML2025
  4. 4Low-dose chemotherapy for induction in pediatric AML: Retrospective outcome analysis across expanded cohorts2025
  5. 5High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen2025